Skip to main content

Table 3 The clinical outcomes of study participants

From: The effects of Taurine supplementation on inflammatory markers and clinical outcomes in patients with traumatic brain injury: a double-blind randomized controlled trial

Variable Taurine (n = 16) Control (n = 16) p-value*
APACHEII score
 Day 1 14 (12, 17) 13 (11, 15) 0.34
 Day 14 12 (9, 13) 13 (9, 14) 0.31
 Changes (1, 14) −4 (−6, −1) −1 (− 4, 2) 0.05
p-value¥ 0.003 0.32  
SOFA score
 Day 1 8 (6, 9) 8 (6, 9) 0.56
 Day 14 5 (4, 6) 7 (5, 8) 0.02
 Changes (1, 14) −3 (−4, −1) −1 (−3, 1) 0.06
p-value¥ 0.003 0.06  
GCS
 Day 1 7 (7, 7) 7 (7, 8) 0.18
 Day 14 9 (7, 10) 8 (6, 9) 0.17
 Changes (1, 14) 2 (0, 3) 0.0 (−1, 1) 0.03
p-value¥ 0.002 0.30  
30-day Mortality (N (%))    0.33
 Yes 1 (6.3) 4 (25)  
 No 15 (93.8) 12 (75)  
Days on mechanical ventilation 18 ± 9 23 ± 14 0.26
Length of ICU stay 22 (17, 31) 21 (18, 39) 0.96
  1. Values are presented as mean ± SD, median (IQR) or Frequency (percent). Independent Samples T test was used for days on mechanical ventilation, Fisher’s exact test for 30-day mortality and Mann-Whitney U test for others. Within group comparison was made by by Wilcoxon for APACHEII and SOFA scores and GCS. *p-value for comparison between group; ¥ p-value for comparison within group.